New Atlas4h
Weight-loss pill passes important safety test in clinical trial
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
The Motley Fool10h
Is Viking Therapeutics a Buy on the Dip?
Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The ...
Worried about the future? History proves it’s hard to predict
Fifty years ago, 20 of the world's brightest people tried to predict life in 2024. They got an awful lot wrong.
Ozempic’s maker wants the US government to ban cheaper versions of the high-priced $969 injection weight-loss drug – claims the formula is ‘too complex’ to cop…
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
BioPharma Dive2d
What RFK Jr.’s influence on Trump could mean for pharma
Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...
Becker's Hospital Review2d
3 Ozempic updates: Competition, warnings and potential uses
A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...